Understand Market Access Trends in the US, Europe and Emerging Markets

April 10, 2019

Rising drug spending and increased desire for expenditure controls are consistent themes across the US, Europe, and emerging markets. With governments and private healthcare systems under increasing pressure to fund high-cost, innovative therapies, which often launch with limited clinical trial evidence, payers are looking towards new and enhanced reimbursement processes which align drug funding with patient value. Based on these growing demands, the healthcare policy environment remains fluid, with payers introducing increasingly restrictive cost-control mechanisms in order to limit the burden on constrained healthcare budgets. 

Spotlight

AL ANDALOUS PHARMACEUTICAL SERVICES ( APS )

Al Andalous Pharmaceutical Services (APS) a privately owned Egyptian company, established in 2006 with a two-fold mission: - Partner with international innovative pharmaceutical and medical device companies to bring innovative specialty products to Egypt and ME region - Provide world-class services and consulting to pharmaceutical industry - focus on regulatory , government affairs and clinical research services APS combines local expertise and access with a multinational perspective, building on the existing leadership and strong position of sister company Al Andalous Medical Company in the Egyptian market.

OTHER WHITEPAPERS
news image

2022 Global Life Sciences Outlook

whitePaper | January 3, 2022

While valuations for the life sciences sector in this past year have been mixed, the underlying performance and outlook for the

Read More
news image

Unlocking iPSCs to Improve CNS Modeling and Drug Discovery

whitePaper | June 15, 2022

To date, therapeutic advances in treating central nervous system (CNS) disorders have been incremental at best. As the global population increases and older demographics begin to make up a disproportionately larger percentage,

Read More
news image

MEETING CURRENT AND FUTURE SERIALISATIONCHALLENGES

whitePaper | December 5, 2022

Serialisation has emerged as a complex challenge for the pharmaceuticals sector which is facing a multiplicity of differing regulations that vary from one country to another.

Read More
news image

Strengthening Engagement and Influence with Key Decision Makers

whitePaper | January 5, 2023

This report follows up on the jointly hosted Pharmaforce and elandas webinar which took place on July, 12, 2016, featuring contributions from participating industry leaders who formed the expert panel, as well as the live contributions of the audience of healthcare sales and marketing professionals.

Read More
news image

Paving the way for pharma R&D to use FAIR data

whitePaper | December 16, 2019

The use of FAIR (Findable, Accessible, Interoperable and Reusable) data in drug discovery and development could be transformational. But the pharma industry has been slow to embrace FAIR data — partially because of difficulties in establishing the necessary infrastructure and because of internal culture.

Read More
news image

Pharma R&D Annual Review 2022 Navigating the Landscape

whitePaper | May 7, 2022

Citeline, Welcome to Pharmaprojects' 2022 reviews of trends in pharmaceutical R&D. Take a look at the evolution of pharma R&D and in this article, examine the state of play at the start of 2022.

Read More

Spotlight

AL ANDALOUS PHARMACEUTICAL SERVICES ( APS )

Al Andalous Pharmaceutical Services (APS) a privately owned Egyptian company, established in 2006 with a two-fold mission: - Partner with international innovative pharmaceutical and medical device companies to bring innovative specialty products to Egypt and ME region - Provide world-class services and consulting to pharmaceutical industry - focus on regulatory , government affairs and clinical research services APS combines local expertise and access with a multinational perspective, building on the existing leadership and strong position of sister company Al Andalous Medical Company in the Egyptian market.

Events